Dora Hammerl

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma

P. Sonneveld, W. Gregory, B. van der Holt, 2021, Cancers.

Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer

J. Foekens, A. Sieuwerts, M. Smid, 2018, Scientific Reports.

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer

M. Timmermans, M. Smid, H. Horlings, 2021, Nature Communications.

Cancer germline antigens and tumor-agnostic CD8+ T cell evasion.

R. Debets, D. Hammerl, Dian Kortleve, 2022, Trends in immunology.

Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies.

J. Martens, Z. Trajanoski, Dietmar Rieder, 2018, Trends in immunology.

Breast cancer genomics and immuno-oncological markers to guide immune therapies.

S. Sleijfer, J. Martens, M. Smid, 2017, Seminars in cancer biology.

Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?

M. Kok, R. Debets, D. Hammerl, 2018, Modern Pathology.